. Author manuscript; available in PMC: 2023 May 14.

Published in final edited form as: Clin Cancer Res. 2022 Nov 14;28(22):4907–4916. doi: 10.1158/1078-0432.CCR-22-1547

Table 2.

Clinical characteristics at the time of ICI initiation

XPID	Source	Histologic Subtype	IMDC score	Prior Therapy	ICI	Best OR	Patient Tumor PD-L1 IHC (%)	TG PD-L1 IHC (%)	PFS (mos.)
XP813	Met. (Spinal Cord)	ccRCC	Poor	Pazo, Eve, Axi, Bev	Nivo	PD	0^a	1 – 5	3.3
XP925	Met. (RP Mass)	pRCC	Fav.	None	Nivo	PD	15	10 – 15	4.30
XP818	Met. (Spinal Cord)	ccRCC	Poor	HDIL2, Axi	Nivo, Nivo+Ipi	MR	1^a	0	5.38
XP945	Primary	ccRCC	Int.	HDIL2, Pazo	Nivo	PR	30	40 – 70	27.7

^a:

tumorgraft lines generated from progressive lesions after ICI.

Abbreviations: PFS (mos), progression free survival in months from the time of starting ICI therapy; Axi, axitinib; Bev, bevacizumab; Eve, everolimus; Fav., favorable; HDIL2, High-Dose Interleukin 2; Int, intermediate; mos., months; MR, mixed response; Pazo, Pazopanib; PD, progressive disease; PFS, progression free survival; PR, partial response; RP, retroperitoneal; XPID, xenograft project line ID; Met., metastases; OR, Objective response.